Joensuu Heikki, Lehtimäki Tiina, Holli Kaija, Elomaa Liisa, Turpeenniemi-Hujanen Taina, Kataja Vesa, Anttila Ahti, Lundin Mikael, Isola Jorma, Lundin Johan
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
JAMA. 2004 Sep 1;292(9):1064-73. doi: 10.1001/jama.292.9.1064.
Selection of systemic adjuvant therapies for women diagnosed as having breast cancer is based on risk estimations for cancer recurrence. In such estimations, tumors detected by mammography screening are considered to be associated with a similar risk of recurrence as tumors of similar size found by other methods.
To compare the risk of recurrence and survival among women with cancerous tumors detected by mammography screening compared with other methods (outside of screening).
DESIGN, SETTING, AND PATIENTS: Retrospective study comparing clinical, histopathological, and biological features of cancerous tumors detected by mammography screening compared with tumors detected outside of screening. Women diagnosed as having breast cancer in 1991 or 1992 were identified from the Finnish Cancer Registry (n = 2842). The median follow-up time was 9.5 years. Cancer biological variables were analyzed from tumor tissue microarrays using immunohistochemistry or in situ hybridization and included ERBB2, TP53, and MK167 expression and ERBB2 amplification data.
Univariate and multivariate analyses of potential risk factors for distant recurrence of breast cancer and 10-year survival.
Of the 1983 women with unilateral invasive breast cancer, data on tumor diameter were available for 1918 women. Women with cancerous tumors detected by mammography screening had better estimated 10-year distant disease-free survival than women with tumors found outside of screening (tumor size of < or =10 mm [n = 386] 92% vs 85% [P =.04]; 11-20 mm [n = 808] 88% vs 76% [P<.001]; 21-30 mm [n = 409] 86% vs 63% [P =.008]; >30 mm [n = 315] 68% vs 50% [P =.12], respectively). In a Cox multivariate model that included cancer biological factors, the relative hazard ratio for distant recurrence among women with tumors detected outside of screening (HR, 1.90; 95% confidence interval, 1.15-3.11) was significantly higher than among women with tumors detected by mammography screening (P =.01). Breast cancer diagnosis by mammography screening was an independent prognostic variable reducing the relative HR for distant recurrence. This effect was equal to or greater than the effect of 1-cm decrease in tumor diameter (HR, 1.20; 95% confidence interval, 1.10-1.31).
Cancerous tumors detected by mammography screening are associated with a better prognosis than tumors of similar size found outside of screening. The risk of distant metastases is overestimated for women diagnosed as having cancer by mammography screening unless the method of detection is taken into account in risk estimations.
对于被诊断患有乳腺癌的女性,全身辅助治疗的选择基于癌症复发风险评估。在此类评估中,乳腺钼靶筛查发现的肿瘤被认为与通过其他方法发现的大小相似的肿瘤具有相似的复发风险。
比较乳腺钼靶筛查发现的癌性肿瘤女性与其他方法(筛查之外)发现的癌性肿瘤女性的复发风险和生存率。
设计、设置和患者:一项回顾性研究,比较乳腺钼靶筛查发现的癌性肿瘤与筛查之外发现的肿瘤的临床、组织病理学和生物学特征。从芬兰癌症登记处识别出1991年或1992年被诊断患有乳腺癌的女性(n = 2842)。中位随访时间为9.5年。使用免疫组织化学或原位杂交从肿瘤组织微阵列分析癌症生物学变量,包括ERBB2、TP53和MK167表达以及ERBB2扩增数据。
对乳腺癌远处复发的潜在风险因素和10年生存率进行单因素和多因素分析。
在1983例单侧浸润性乳腺癌女性中,有1918例女性可获得肿瘤直径数据。乳腺钼靶筛查发现癌性肿瘤的女性估计10年远处无病生存率优于筛查之外发现肿瘤的女性(肿瘤大小≤10 mm [n = 386],92%对85% [P = 0.04];11 - 20 mm [n = 808],88%对76% [P < 0.用免疫组织化学或原位杂交从肿瘤组织微阵列分析癌症生物学变量,包括ERBB2、TP53和MK167表达以及ERBB2扩增数据。
对乳腺癌远处复发的潜在风险因素和10年生存率进行单因素和多因素分析。
在1983例单侧浸润性乳腺癌女性中,有1918例女性可获得肿瘤直径数据。乳腺钼靶筛查发现癌性肿瘤的女性估计10年远处无病生存率优于筛查之外发现肿瘤的女性(肿瘤大小≤10 mm [n = 386],92%对85% [P = 0.04];11 - 20 mm [n = 808],88%对76% [P < 0.001];21 - 30 mm [n = 409],86%对63% [P = 0.008];> 30 mm [n = 315],68%对50% [P = 0.12])。在包含癌症生物学因素的Cox多因素模型中,筛查之外发现肿瘤的女性远处复发的相对风险比(HR,1.90;95%置信区间,1.15 - 3.11)显著高于乳腺钼靶筛查发现肿瘤的女性(P = 0.01)。乳腺钼靶筛查诊断乳腺癌是一个独立的预后变量,可降低远处复发的相对风险比。这种效应等于或大于肿瘤直径减小1 cm的效应(HR,1.20;95%置信区间,1.10 - 1.31)。
乳腺钼靶筛查发现的癌性肿瘤比筛查之外发现的大小相似的肿瘤预后更好。对于通过乳腺钼靶筛查被诊断患有癌症的女性,远处转移风险被高估,除非在风险评估中考虑检测方法。001];21 - 30 mm [n = 409],86%对63% [P = 0.008];> 30 mm [n = 315],68%对50% [P = 0.12])。在包含癌症生物学因素的Cox多因素模型中,筛查之外发现肿瘤的女性远处复发的相对风险比(HR,1.90;95%置信区间,1.15 - 3.11)显著高于乳腺钼靶筛查发现肿瘤的女性(P = 0.01)。乳腺钼靶筛查诊断乳腺癌是一个独立的预后变量,可降低远处复发的相对风险比。这种效应等于或大于肿瘤直径减小1 cm的效应(HR,1.20;95%置信区间,1.10 - 1.31)。
乳腺钼靶筛查发现的癌性肿瘤比筛查之外发现的大小相似的肿瘤预后更好。对于通过乳腺钼靶筛查被诊断患有癌症的女性,远处转移风险被高估,除非在风险评估中考虑检测方法。